Healthcare can be complicated.
Your cardiology news shouldn’t be.
Join thousands of cardiology leaders today.
Cardiology October 24, 2024
The State of Cardiology Employment October 24, 2024
MedAxiom released its 12th annual Cardiovascular Provider Compensation and Production Report, providing an in-depth look at the current state of working in cardiology. The massive 60-page report (n=5,663 providers, 202 programs, 2023 data) outlined four notable employment trends… Rising PE Ownership – Nearly 50% of surveyed private practice groups were also part of a private […]
Pharmaceuticals October 21, 2024
Exploring Semaglutide’s Cardiovascular Impact October 21, 2024
JACC took a deep dive into semaglutide’s cardiovascular impact, publishing six analyses of three separate trials that delivered new insights into the drug’s heart benefits, while raising even more questions about how it works. One STEP-HFpEF trial analysis showed that patients with obesity-related HFpEF on semaglutide achieved cardiac remodeling benefits beyond the impact of weight […]
Atrial Fibrillation October 17, 2024
InCarda Gets Mixed Results in AFib Inhaler Trial October 17, 2024
AFib inhalers took a small step closer to becoming a reality after InCarda Therapeutics’ Phase 3 RESTORE-1 trial showed that its FlecIH-103 inhaled flecainide formulation can rapidly convert paroxysmal AFib to normal sinus rhythm. However, challenges with the study suggest that InCarda has more work to do in order to achieve this reality. The new […]
Cholesterol Reduction October 10, 2024
AstraZeneca Adds Lp(a) Candidate with CSPC Licensing Move October 10, 2024
AstraZeneca expanded its cardiovascular pipeline this week, signing an exclusive license agreement for CSPC Pharmaceutical Group’s Lp(a) disruptor candidate, YS2302018. The deal comes with a $100M upfront investment that could reach $1.92B depending on further milestones. CSPC’s YS2302018 addresses a sizable target market, noting that nearly 70% of patients with CVD aren’t meeting guideline-directed LDL-C […]